Coronavirus SARS-CoV-2: nota informativa sobre la seguretat dels inhibidors del cotransportador sodi-glucosa tipus 2 (ISGLT2) en el context de la crisi de la COVID-19 [fullet]
Abstract
Recommendations on ISGLT2 treatment have been published in the context of SARS-CoV-2 coronavirus infection from a single English-language hospital consortium, which have not been assumed by the rest of the British NHS. These recommendations mention data that is not public or quantified. In the case of patients with diabetes with symptoms and suspected coronavirus infection (fever, cough, shortness of breath) or in patients with diabetes and severe non-COVID-19 intercurrent diseases, scientific societies and health authorities recommend discontinuing treatment with ISGLT2 and adjust other hypoglycemic treatments during the active illness period.
Keywords
Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Sodium glucose glucose transporter type 2 inhibitors; ISGLT2; Diabetes; Treatment
Bibliographic citation
Programa d’Harmonització Farmacoterapèutica. Coronavirus SARS-CoV-2: nota informativa sobre la seguretat dels inhibidors del cotransportador sodi-glucosa tipus 2 (ISGLT2) en el context de la crisi de la COVID-19 [fullet]. Barcelona: Servei Català de la Salut; 2020.
Audience
Professionals
Use this identifier for quote and/or link this document
https://hdl.handle.net/11351/4863This item appears in following collections
The following license files are associated with this item: